CL King analyst Andrew Wolf initiates coverage on SpartanNash (NASDAQ:SPTN) with a Neutral rating.
Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS Trial
The Sean M. Healey & AMG Center for ALS at Mass General received approval from the FDA and the Mass…